KR20110076347A - Pharmaceutical composition and health improving food composition containing ginseng extracts for preventing or treating benign postatic hyperplasia - Google Patents

Abstract

PURPOSE: A composition containing ginseng extract is provided to significantly suppress prostatic hyperplasia and to remarkably suppress growth of benign prostate tissues. CONSTITUTION: A pharmaceutical composition for preventing or treating prostatic hyperplasia contains extract of ginseng, Rhynchosia Nulubilis, and green tea as an active ingredient. The ginseng extract is prepared by pulverizing 600g of ginseng, adding 12 L of water, performing hot water extraction at 100°C for 3 hours, concentrating in a vacuum condenser at 45°C, and freeze-drying. The Rhynchosia Nulubilis extract is prepared by pulverizing 600g of Rhynchosia Nulubilis, adding 12L of water, performing at 100°C for three hours, concentrating at 45°C, and freeze-drying.

Description

PHARMACEUTICAL COMPOSITION AND HEALTH IMPROVING FOOD COMPOSITION CONTAINING GINSENG EXTRACTS FOR PREVENTING OR TREATING BENIGN POSTATIC HYPERPLASIA}

The present invention relates to a composition for the prevention or treatment of enlarged prostate, comprising ginseng extract, and more particularly, to a pharmaceutical composition for the prevention or treatment of enlarged prostate containing extracts of ginseng, bean sprouts and green tea as active ingredients It relates to a functional food composition.

The prostate gland is a part of the semen, making the prostate fluid to nourish and sperm sperm and to protect the urinary tract, which is located just below the bladder and the urethra, which is the passage of the bladder.

Benign Postatic Hyperplasia (BPH) is a disease in which the prostate gland is abnormally enlarged, particularly after 40 to 50 years, when the prostate grows, the urethra is urged to interfere with the flow of urine, resulting in abnormal urination. These symptoms of urination abnormalities not only can't hold the urine, but the urine stem is thin and weak, and even if you try to urinate, you will not be able to see it immediately, and after you urinate, you will have residual urine (the urine remains in the bladder). It hurts, and also frequent urine affects the kidneys, which eventually causes chronic kidney failure due to a decrease in kidney function. In addition, the stagnant urine thus provides a good condition for the growth of bacteria in the prostate and urethra, there was a problem that can easily cause complications, such as inflammation, stones.

Recently, prostatectomy or laser removal method is used for the treatment of prostate hypertrophy, but it is only temporary treatment and cannot prevent the enlargement of the prostate, and the drug used for treatment is alpha-adrenergic antagonist ( Alpha-adrenergicantagonists are drugs that inhibit the tone of the prostate and drugs that reduce androgen hormones to block the expansion of the prostate, but many side effects are difficult to use.

In addition, 5-alpha reductase inhibitor in the treatment of prostatic hyperplasia does not affect testosterone, which exhibits male hormone action, and selectively inhibits the production of dihydrotestosterone, thereby expressing an anti-androgen effect and without the side effects found in anticancer hormone drugs. It is recognized as a safe and causative treatment that can treat urination disorder by reducing the enlarged prostate. Therefore, compounds such as finasteride (component name: Finasteride, product name: Proxcar, Merck Co., Ltd.) that inhibit the action of 5-alpha-reductase to inhibit the production of dihydrotestosterone in tissues are currently used for the treatment of enlarged prostate. (US Patent No. 4,377,584, US Patent No. 4,760,071, Korean Patent Publication No. 2003-22763, Korean Patent Publication No. 2000-0075651, Korean Patent Publication No. 2004-0016559).

Drug treatment includes a drug called Alpha Blocker, which reduces the symptoms of enlarged prostate. However, it does not actually reduce the enlargement of the prostate gland, but rather relaxes the muscles of the prostate or bladder, thereby lightening the symptoms. There is also a Herbal Medication called Saw Palmetto, which is somewhat helpful for prostatic hyperplasia. Genetic factors can be considered as another cause, and the incidence is high in people who eat foods high in fat (especially animal fat).

In addition, prostate cancer is one of the most common malignancies in the United States, where animal fat is high. Statistics show that 235,000 people were diagnosed in 2006 and about 27,000 died. The cause of this prostate cancer is unknown, but age is a risk factor. More than 70% of prostate cancers found each year are after age 65.

 Therefore, the present inventors continue to develop a natural pharmaceutical composition having an inhibitory effect on the enlarged prostate ginseng, ginseng, mouse eye and green tea extract as an active ingredient has not been reported so far in relation to the treatment of enlarged prostate The present invention has been completed by discovering that the composition has an inhibitory effect on prostatic hyperplasia.

An object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of enlarged prostate.

Another object of the present invention is to provide a health functional food composition having a prophylactic effect against prostatic hyperplasia.

In order to achieve the above object, the present invention provides a pharmaceutical composition for preventing or treating enlarged prostate gland containing ginseng, rat eye and green tea extract as an active ingredient.

In order to achieve the above another object, the present invention provides a health functional food composition having a prophylactic effect against prostatic hyperplasia containing an extract of ginseng, rat eye and green tea.

The composition comprising the extract of ginseng, rat bean and green tea of the present invention as an active ingredient significantly inhibits the enlargement of the prostate gland, significantly inhibits the growth of benign prostate tissue, thereby effectively preventing and treating the enlarged prostate gland, It can be usefully used as a pharmaceutical composition for the prophylaxis or treatment of and a health functional food composition.

The technical terms and scientific terms used in the present invention can be construed as meaning ordinary meanings understood by those of ordinary skill in the art without departing from the scope of the present invention.

In the present invention, the pharmaceutical composition for treating prostatic hyperplasia means a composition capable of treating prostatic hyperplasia by administering the herbal composition according to the present invention for the treatment of prostatic hyperplasia caused by excessive dehydrotestosterone, and specifically, such a prostate Hypertrophy treatment effect means healing the enlarged prostate to normal size.

The pharmaceutical composition for preventing or treating the enlarged prostate of the present invention contains an extract of ginseng, rat eye and green tea as an active ingredient, and 50 to 150 parts by weight of rat eye extract and 50 to green tea extract based on 100 parts by weight of ginseng extract. It is contained in an amount of 150 parts by weight.

The scientific study on the active ingredient of Panax ginseng CAMAYER used in the present invention was carried out in 1854 by Garriques of the United States to isolate an amorphous substance (C ₃₂ H ₅₆ O ₁₄ ), which is a kind of saponin mixture from American ginseng, panaquilon It has been studied steadily for about 150 years since it was reported to academia. In the early 1900s, research on the separation of saponin and saponogenin from Korean and Japanese cultivated ginseng was carried out in the early 1900s, and in the 1930s, saponin, prosapogenin, and panaxin from Korean ginseng. ) Are separated. In 1957, Soviet pharmacologist Brekhman reported the central nervous system excitability and anti-fatigue effect of ginseng saponin, indicating that the active ingredient of ginseng is saponin. This led to the spread of research on ginseng saponins from the early 1960s, and the chemical structure of saponins was revealed in 1962. After that, saponin is separated from ginseng, and it is named ginsenoside, and its pharmacological activity is studied in full scale. In addition to saponin, the main components of ginseng are essential oils, polyacexylene-based compounds, phenolic compounds, and peptides. Analysis of ingredients such as alkaloids and vitamins was extensive. Recently, it has been gradually found that there are various pharmacological activities in non-saponin fractions other than the saponin component.

Rat eye bean ( Rhynchosia) used in the present invention Also called Nulubilis Loureir) or Seomoktae. The description of this is that in the Hyangyakbangbang, the rat's eyes are sweet, warm in nature, toxic and char-grilled, soaked in alcohol and consumed little by little. It has been reported to be effective in controlling hot water and poisoning by acting and neutralizing.

It is also reported that Seomokmok (Rice Eye Beans) controls the genus and removes all poisons through the vein. In Bojebang, it is said that drinking boiled black soybeans and lotus root decoction is effective when stool is bleeding after seeing feces. . In the herbaceous tree, rat eye is said to control kidney disease, suppress all wind fever, revitalize blood, and detoxify all poisons.

Green tea used in the present invention was found to have the strongest anticancer effect among the tea and anticancer effect of inhibiting the synthesis of N-nitroso compounds. Ingredients contain many antioxidants, which inhibit aging, and trace elements such as zinc, copper, iron, manganese, fluorine, trace minerals such as caffeine, polyphenols, and vitamin P. It is rich in vitamin C and contains five times the amount of lemon vitamin C, which keeps the skin rough, gives elasticity to the subcutaneous tissue, and keeps it moisturizing. Tea has a unique ingredient called EGDg that reduces cholesterol and allows it to be excreted from the body. Tea, in particular, is rich in vitamin C, which promotes the oxidation of fat and boosts the release of cholesterol. Tea leaves also contain depirine, catechin, and deanine, which are not found in coffee, which combine with caffeine to make caffeine an insoluble ingredient or inhibit its activity.

In the present invention, ginseng, rat eye bean and green tea may be used after mixing and extracting each ginseng extract, mouse eye extract and green tea extract.

The extraction of each active ingredient is pulverized 600 g of each herbal medicine, put in 12L of water and extracted with hot water at 100 ℃ for 3 hours, concentrated in a vacuum concentrator at 45 ℃ until the solid content is 30%, and the concentrate is lyophilized The herbal extract powder can be obtained.

The dosage of the composition used to achieve the therapeutic effect according to the present invention depends on the method of administration of silver, the age of the subject to be treated and the severity of the disease, but the adult daily amount of the active ingredient in the composition according to the present invention is 20 to 150 mg. It is preferably 40 to 100mg, both oral or topical administration is possible depending on the formulation.

In the case of oral administration of the pharmaceutical composition according to the present invention can be prepared in all conventional forms, for example tablets, powders, dry syrups, chewable tablets, granules, chewing tablets, capsules, soft capsules, pills, It can exist in various forms, such as drink, sublingual tablet, and the like. Depending on the nature of the disease state to be treated, the stage of the disease, and other relevant circumstances, a suitable dosage form or mode may be readily selected and may comprise one or more pharmaceutically acceptable excipients when the composition according to the invention is a tablet. The proportion and nature of such excipients may be determined by the solubility and chemical properties of the selected tablet, the chosen route of administration, and standard pharmaceutical practice.

More specifically, the compositions according to the invention may comprise a therapeutically effective amount of the above-mentioned active ingredient as an essential ingredient together with one or more pharmaceutically acceptable excipients. Excipient materials can be solid or semisolid materials that can function as a vehicle or medium of the active ingredient, and suitable excipients are well known in the art. Excipient materials may be selected in connection with the intended dosage form, specifically for tablets, powders, chewable tablets, granules, chewing tablets, capsules, soft capsules, pills, sublingual tablets or syrups, The therapeutically active drug component may be combined with any oral nontoxic pharmaceutically acceptable inert excipient such as lactose or starch. Optionally, the pharmaceutical tablets of the present invention may contain a binder such as amorphous cellulose, gum tragacanth or gelatin, a disintegrant such as alginic acid, a lubricant such as magnesium stearate, a glidant such as colloidal silicon dioxide, sucrose It may also contain sweetening agents such as oz or saccharin, colorants or flavoring agents such as peppermint or methyl salicylate.

Tablets can be the most advantageous oral unit dosage form because of their ease of administration, and tablets can be coated with sugars, shellac or other enteric coatings by standard aqueous or non-aqueous techniques, if desired.

The pharmaceutical composition comprising the ginseng extract, rat eye extract and green tea extract of the present invention as an active ingredient is composed of foods and has no side effects and is excellent in safety.

The composition comprising the ginseng, rat eye and green tea extract of the present invention as an active ingredient significantly inhibits the enlargement of the prostate gland, it can effectively prevent and treat prostatic hyperplasia by significantly inhibiting the growth of benign prostate tissue.

In addition, the present invention provides a health functional food composition having a prostatic hypertrophy prevention effect, including ginseng extract, rat eye extract and green tea extract.

The health functional food composition of the present invention has no special limitation except for containing the herbal extract powder as an essential ingredient in the indicated ratio, and may contain various flavors or natural carbohydrates, etc. as additional ingredients, such as ordinary drinks. . Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And conventional sugars such as polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those mentioned above, natural flavoring agents (tauumatin, stevia extract (e.g., rebaudioside A, glycyrrhizin, etc.), and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. The ratio of said natural carbohydrate is generally about 1-20g, preferably about 5-12g per 100m1 of the composition of the present invention.

In addition to the above, the composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, coloring and neutralizing agents (such as cheese and chocolate), pectic acid and salts thereof, alginic acid and salts thereof. , Organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like. The compositions of the present invention may also contain pulp for the production of natural fruit juices and fruit juice beverages and vegetable beverages. These components can be used independently or in combination. The proportion of such additives is not so critical, but is generally selected in the range of 0 to about 20 parts by weight per 100 parts by weight of the composition of the present invention.

Foods to which the herbal extract powder of the present invention may be added for development for health foods include various foods, beverages, gums, vitamin complexes, health supplements, and the like.

Hereinafter, the present invention will be described in more detail based on the following examples. However, the following examples are only for illustrating the present invention and the scope of the present invention is not limited thereto.

Preparation Example 1 Preparation of Ginseng Extract

600 g of ginseng was pulverized, placed in 12 L of water, extracted with hot water at 100 ° C. for 3 hours, and concentrated at 45 ° C. until the solid content reached 30%. The concentrate was lyophilized to obtain 120 g of ginseng extract powder.

Preparation Example 2 Preparation of Rat Eye Bean Extract

Grind 600 g of rat eye, put it in 12 L of water, extract hot water at 100 ° C. for 3 hours, and concentrate it at 45 ° C. until the solid content reaches 30%. The concentrate is lyophilized to obtain 86 g of mouse bean extract powder. Obtained.

Preparation Example 3 Preparation of Green Tea Extract

600 g of dried green tea leaves were placed in 12 L of water, extracted with hot water at 100 ° C. for 3 hours, and concentrated at 45 ° C. until the solid content reached 30%. The concentrate was lyophilized to obtain 100 g of green tea extract powder.

Example 1 Preparation of a Composition Containing Ginseng, Root Bean, and Green Tea Extract

20 g each of ginseng, rat bean and green tea extract powders obtained in Preparation Examples 1, 2, and 3 were added, and 1L of water was added to the mixture of 60 g. The composition was slowly heated to prepare a composition containing ginseng, red bean and green tea extract. Hereinafter referred to as 'YO-1105'.

Example 2 Preparation of a Composition Containing Ginseng, Root Bean, and Green Tea Extracts

The ginseng, rat eye bean and green tea extract powders obtained in Preparation Examples 1, 2 and 3 were combined with 20 g of ginseng, 30 g mouse eye bean and 20 g of green tea extract, respectively, and 1.2L of water was added to the mixture prepared in a total of 70 g. In the same manner as to prepare a composition containing ginseng, rat eye and green tea extract.

Example 3 Preparation of a Composition Containing Ginseng, Root Bean, and Green Tea Extracts

The ginseng, rat eye and green tea extract powders obtained in Preparation Examples 1, 2 and 3 were combined with 20 g of ginseng, 20 g of rat eye, and 30 g of green tea extract, respectively, and 1.2L of water was added to the mixture of 70 g of the mixture. In the same manner as to prepare a composition containing ginseng, rat eye and green tea extract.

Example 4 Preparation of a Composition Containing Ginseng, Root Bean, and Green Tea Extracts

The ginseng, rat eye and green tea extract powders obtained in Preparation Examples 1, 2 and 3 were combined with 30 g of ginseng, 20 g of rat eye, and 20 g of green tea extract, respectively, and then 1.2L of water was added to the mixture to prepare a total of 70 g. In the same manner as to prepare a composition containing ginseng, rat eye and green tea extract.

Example 5 Preparation of a Composition Containing Distilled Ginseng, Root Bean, and Green Tea Extract

20 g each of ginseng, red bean sprouts, and green tea extracts are mixed in a 3L Erlenmeyer flask, and 1 liter of water is added to the mixture.Then, the heating is started and cooled for 1 hour before being discharged from the flask inlet. The collection was stopped after about 5 hours of obtaining 250 ml of distillate by capturing the distillate which connected the steam to the Lichrich cooler.

Example 6 Preparation of a Composition Containing Distilled Ginseng, Root Bean, and Green Tea Extract

20 g of ginseng, 20 g of mouse eye bean, and 30 g of green tea extract were mixed in a 3 L volume Erlenmeyer flask, 1.2 L of water was added to the mixture, and a distilled herbal composition was prepared in the same manner as in Example 5.

Example 7 Preparation of a Composition Containing Distilled Ginseng, Root Bean, and Green Tea Extract

20 g of ginseng, 30 g of mouse eye beans, and 30 g of green tea extract were mixed in a 3 L volume Erlenmeyer flask, 1.2 L of water was added to the mixture, and a distilled herbal composition was prepared in the same manner as in Example 5.

Example 7 Preparation of a Composition Containing Distilled Ginseng, Root Bean, and Green Tea Extract

30 g of ginseng, 20 g of red eye beans, and 20 g of green tea extract were mixed in a 3 L volume Erlenmeyer flask, 1.2 L of water was added to the mixture, and a distilled herbal composition was prepared in the same manner as in Example 5.

Test Example 1 In Vivo Experiment for Observation of Prostatic Hypertrophy Effect of Castrated Rats

In order to confirm the inhibitory effect on the prostate hypertrophy of the composition comprising the ginseng, rat eye and green tea extract of the present invention, Wistar rats (8 weeks old 250g, male (central laboratory animals)) as follows In vivo testing was performed.

As a comparative group, finasteride, which is known as an inhibitor of testosterone 5-alpha reductase, is known as an active substance exhibiting an excellent anti-hair loss effect of androgenetic alopecia and an excellent therapeutic effect against benign prostatic hyperplasia.

The male Wistar rats were purified for 1 week, after ether anesthesia, castrated and allowed to rest for 1 week.The group of each subject was normal, prostatic hypertrophy induced by hormonal stimulation (control), and hormonal stimulation. Experimental group 1 administered the composition according to the present invention to confirm the therapeutic effect after prostate hypertrophy induced by the comparison group administered the finasteride after prostate hypertrophy induced by hormonal stimulation, and the composition according to the present invention for confirming the prophylactic effect It was divided into experimental group 2 administered.

To induce prostate hypertrophy, testosterone (TP) was dissolved in sesame oil for 4 weeks and injected subcutaneously at 300 mg / kg / day. The composition of the present invention was orally administered in an amount of 40 mg / kg / day or 100 mg / kg / day, and 5 mg / kg of finasteride used as a comparison group was orally administered for 4 weeks. The experimental detailed method of administration is summarized in Table 1 below.

After four consecutive weeks of oral administration, the rats were distal to the cervical spine and opened, and the prostate was removed and weighed. The results are shown in Table 2 and FIG. 1.

As shown in FIG. 1, the weight of the prostate in the normal group subjected to castration alone was 0.024 g / kg, and the weight of the control group inducing prostate hypertrophy by taking TP was 0.18 g / kg, which is 7.5 times higher than the weight of the normal group. Can be. In addition, the prostate weights of the experimental group (40 mg / kg and 100 mg / kg) administered with the composition of the present invention after inducing prostate hypertrophy were 0.082 g / kg and 0.078 g / kg, respectively, of 54.5% and 56.7% of the control group, respectively. It showed a hypertrophy inhibitory effect. In addition, the weight of the prostate in the experimental group (40 mg / kg and 100 mg / kg) administered with the composition of the present invention without induction of prostate hypertrophy was 0.021 g / kg and 0.019 g / kg, respectively, similar to that of the normal group to prevent prostatic hyperplasia. You can see that there is.

Test Example 2 : Changes in Prostate Epithelial Cells by Prostate Tissue Staining in Wister Rats

Following Test Example 1, changes in the shape of prostate epithelial cells were observed. Normal group (A), comparative group administered with finasteride after prostate hypertrophy induced by hormone stimulation (B), experimental group 1 (40 g / kg) and hormone stimulation administered the composition according to the present invention after prostatic hypertrophy induced by hormone stimulation After removing the prostate tissue sections from the control group (D), which is a prostatic hypertrophy group, and washing them with water, the sections were stained for 1 minute using a Meyer hematoclinin dye (Merck), and then washed again with running water for 10 minutes. It was. Subsequently, the samples were removed with ethanol, washed with xylene, and then observed with prostate epithelial cells under a microscope. The results are shown in FIG.

As shown in Figure 2, A, B and C is a low columnar epithelial cells of one layer consisting of luminal endocrine cells (secretory luminal cells), the epithelial cells are not proliferated, whereas in the control group causing prostate hyperplasia with testosterone Hyperplasia showed an increase in the number and height of epithelial cells.

The composition comprising the extract of ginseng, rat bean and green tea of the present invention as an active ingredient significantly inhibits the enlargement of the prostate gland, significantly inhibits the growth of benign prostate tissue, thereby effectively preventing and treating the enlarged prostate gland, It can be usefully used as a pharmaceutical composition for the prophylaxis or treatment of and a health functional food composition.

1 is a graph showing the effect of reducing the weight of the prostate gland by the composition of the present invention.

Figure 2 is a micrograph of the prostate epithelial cells showing the effect of inhibiting prostatic hypertrophy by the composition of the present invention.

Claims (10)

A pharmaceutical composition for preventing or treating enlarged prostate gland, which contains extracts of ginseng, red eye bean and green tea as active ingredients. The method of claim 1, The ginseng extract is pulverized 600g ginseng, put into 12L of water and extracted with hot water at 100 ° C. for 3 hours, concentrated at 45 ° C. until the solid content is 30%, and the concentrate is obtained by lyophilization. Pharmaceutical compositions. The method of claim 1, After extracting 600 g of rat eye beans, crushed 600 g of mouse eye beans, put them in 12 L of water, extract hot water at 100 ° C. for 3 hours, and concentrate them at 45 ° C. until the solid content reaches 30%, and the concentrate was lyophilized. Pharmaceutical composition, characterized in that. The method of claim 1, The green tea extract is 600 g of dried green tea leaves in 12L of water and extracted with hot water at 100 ° C. for 3 hours, and then concentrated at 45 ° C. until the solid content is 30%, and the concentrate is obtained by freeze-drying. Pharmaceutical compositions. The method according to claim 1, wherein Pharmaceutical composition, characterized in that the ginseng extract, mouse eye extract and green tea extract are contained in an amount of 50 to 150 parts by weight and 50 to 150 parts by weight of green tea extract based on 100 parts by weight of ginseng extract. Health functional food composition having a prophylactic effect against prostatic hyperplasia containing ginseng extract, rat eye extract and green tea extract. The method of claim 6, The ginseng extract is pulverized 600g ginseng, put into 12L of water and extracted with hot water at 100 ° C. for 3 hours, concentrated at 45 ° C. until the solid content is 30%, and the concentrate is obtained by lyophilization. Health functional food composition. The method of claim 6, After extracting 600 g of rat eye beans, crushed 600 g of mouse eye beans, put them in 12 L of water, extract hot water at 100 ° C. for 3 hours, and concentrate them at 45 ° C. until the solid content reaches 30%, and the concentrate was lyophilized. Health functional food composition, characterized in that. The method of claim 6, The green tea extract is 600 g of dried green tea leaves in 12L of water, extracted with hot water at 100 ° C. for 3 hours, and concentrated at 45 ° C. until the solid content is 30%, and the concentrate is obtained by lyophilization. Health functional food composition. The method of claim 6, Health functional food composition, characterized in that the ginseng extract, mouse eye extract and green tea extract are contained in an amount of 50 to 150 parts by weight and 50 to 150 parts by weight of green tea extract with respect to 100 parts by weight of ginseng extract, respectively.

Images